1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells

Bibliographic Details
Main Authors: Scott Garforth, Harris Goldstein, Steven Almo, Christopher R Hiner
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
_version_ 1797632420986486784
author Scott Garforth
Harris Goldstein
Steven Almo
Christopher R Hiner
author_facet Scott Garforth
Harris Goldstein
Steven Almo
Christopher R Hiner
author_sort Scott Garforth
collection DOAJ
first_indexed 2024-03-11T11:37:46Z
format Article
id doaj.art-8efb06b8ead147f1a7d91340f55c5509
institution Directory Open Access Journal
issn 2051-1426
language English
last_indexed 2024-03-11T11:37:46Z
publishDate 2023-11-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj.art-8efb06b8ead147f1a7d91340f55c55092023-11-10T12:45:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.11701170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cellsScott Garforth0Harris Goldstein1Steven Almo2Christopher R Hiner31Albert Einstein College of Medicine, Bronx, NY, USA1Albert Einstein College of Medicine, Bronx, NY, USAAlbert Einstein College of Medicine, Bronx, NY, USAAlbert Einstein College of Medicine, Bronx, NY, USA
spellingShingle Scott Garforth
Harris Goldstein
Steven Almo
Christopher R Hiner
1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
Journal for ImmunoTherapy of Cancer
title 1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
title_full 1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
title_fullStr 1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
title_full_unstemmed 1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
title_short 1170 Development of a fusion protein bispecific for a CMV-specific TCR and CD19 which selectively activates and expands CMV-specific CTLs and redirects them to eliminate B cell leukemia cells
title_sort 1170 development of a fusion protein bispecific for a cmv specific tcr and cd19 which selectively activates and expands cmv specific ctls and redirects them to eliminate b cell leukemia cells
work_keys_str_mv AT scottgarforth 1170developmentofafusionproteinbispecificforacmvspecifictcrandcd19whichselectivelyactivatesandexpandscmvspecificctlsandredirectsthemtoeliminatebcellleukemiacells
AT harrisgoldstein 1170developmentofafusionproteinbispecificforacmvspecifictcrandcd19whichselectivelyactivatesandexpandscmvspecificctlsandredirectsthemtoeliminatebcellleukemiacells
AT stevenalmo 1170developmentofafusionproteinbispecificforacmvspecifictcrandcd19whichselectivelyactivatesandexpandscmvspecificctlsandredirectsthemtoeliminatebcellleukemiacells
AT christopherrhiner 1170developmentofafusionproteinbispecificforacmvspecifictcrandcd19whichselectivelyactivatesandexpandscmvspecificctlsandredirectsthemtoeliminatebcellleukemiacells